Podocyte injury of diabetic nephropathy: Novel mechanism discovery and therapeutic prospects

Biomed Pharmacother. 2023 Dec:168:115670. doi: 10.1016/j.biopha.2023.115670. Epub 2023 Oct 13.

Abstract

Diabetic nephropathy (DN) is a severe complication of diabetes mellitus, posing significant challenges in terms of early prevention, clinical diagnosis, and treatment. Consequently, it has emerged as a major contributor to end-stage renal disease. The glomerular filtration barrier, composed of podocytes, endothelial cells, and the glomerular basement membrane, plays a vital role in maintaining renal function. Disruptions in podocyte function, including hypertrophy, shedding, reduced density, and apoptosis, can impair the integrity of the glomerular filtration barrier, resulting in elevated proteinuria, abnormal glomerular filtration rate, and increased creatinine levels. Hence, recent research has increasingly focused on the role of podocyte injury in DN, with a growing emphasis on exploring therapeutic interventions targeting podocyte injury. Studies have revealed that factors such as lipotoxicity, hemodynamic abnormalities, oxidative stress, mitochondrial dysfunction, and impaired autophagy can contribute to podocyte injury. This review aims to summarize the underlying mechanisms of podocyte injury in DN and provide an overview of the current research status regarding experimental drugs targeting podocyte injury in DN. The findings presented herein may offer potential therapeutic targets and strategies for the management of DN associated with podocyte injury.

Keywords: Diabetic nephropathy; Pharmacotherapy; Podocyte injury; Proteinuria.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Endothelial Cells
  • Humans
  • Kidney Failure, Chronic*
  • Podocytes*
  • Proteinuria